A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...
Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...
Morning Overview on MSN
Daraxonrasib, a daily RAS-blocking pill, raised pancreatic cancer survival from 6.7 to 13.2 months with fewer severe side effects than chemo
Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
Investigators evaluated the safety and efficacy of daraxonrasib compared to standard-of-care chemotherapy in patients with ...
Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs).
Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
An international phase 3 clinical trial has found that an investigational oral medication (a daily pill) doubled the median ...
The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results